# INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

> **NCT06209671** · PHASE1 · UNKNOWN · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Leukemia, B-cell

## Interventions

- **BIOLOGICAL:** INS19 CAR-T Cells

## Key facts

- **NCT ID:** NCT06209671
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-15
- **Primary completion:** 2025-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06209671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06209671, "INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06209671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*